Tumor- and Radiation-Related Complications after Ruthenium-106 Brachytherapy in Small to Medium Uveal Melanomas (Part 1)
Klinische Monatsblätter für Augenheilkunde · 01.02.2025 · 242 (02) · 105-115
DOI: 10.1055/a-2268-0985 ↗Kurz gefasst
Fachartikel in der Zeitschrift Klinische Monatsblätter für Augenheilkunde, erschienen am 01.02.2025. Verfasst von Fotios Lalos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Essen, Germany. Hauptthemen laut MEDLINE: Brachytherapy, Melanoma, Uveal Neoplasms, Ruthenium Radioisotopes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Purpose
The purpose of this study was to analyze tumor-related complications after ruthenium-106 brachytherapy in patients with uveal melanoma, with respect to local tumor control, insufficient radiation response, enucleation, and metastasis rate. Patients/Methods and Materials This retrospective study included 608 patients treated consecutively with ruthenium-106 brachytherapy between January 2008 and December 2010 at the Department of Ophthalmology, University Hospital Essen. The occurrence of radiation-induced results was analyzed by estimating the risk by applying the Kaplan-Meier method, i.e., the “time to event” analysis. The Cox model test was used for the univariate and multivariate risk factor analyses. The median follow-up was 51 months after primary treatment.
Results
Tumor recurrence was found in 21 patients (3.5%) and repeated treatment due to insufficient effect after the initial ruthenium-106 brachytherapy was performed in 40 patients (6.6%). The 5-year cumulative risk of recurrence was 4.0% and that of insufficient effect was 7.3%. Thirteen patients (2.1%) underwent a secondary enucleation; 8 because of a local recurrence and 5 because of severe post-brachytherapy complications. The cumulative enucleation risk was 2.3% after 5 years and 2.9% after 10 years, corresponding to eye preservation of 97.7 and 97.1%, respectively. In forty-two patients (7.2%), metastatic disease was diagnosed during the follow-up. The metastatic rate as calculated by the Kaplan-Meier method was 9.0, and 13.1% at 5 and 10 years, respectively.
Conclusion
Our study demonstrated that ruthenium-106 brachytherapy is an excellent treatment option for achieving local tumor control and eye preservation in well-selected patients. The metastatic rate is in agreement with that of previous studies analyzing small to medium size uveal melanomas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, University Hospital of Essen, Germany.
- Department of Radiotherapy, University Hospital of Essen, Germany.
- German Cancer Consortium (DKTK), Heidelberg, Partner Site University Hospital Essen, Essen, Germany.
Zitieren
APA
Lalos, F., Flühs, D., Guberina, M., Bornfeld, N., Stuschke, M., Sauerwein, W., & Bechrakis, N. E. (2025). Tumor- and Radiation-Related Complications after Ruthenium-106 Brachytherapy in Small to Medium Uveal Melanomas (Part 1). Klinische Monatsblätter für Augenheilkunde, 242(02), 105-115. https://doi.org/10.1055/a-2268-0985
Vancouver
Lalos F, Flühs D, Guberina M, Bornfeld N, Stuschke M, Sauerwein W, et al. Tumor- and Radiation-Related Complications after Ruthenium-106 Brachytherapy in Small to Medium Uveal Melanomas (Part 1). Klinische Monatsblätter für Augenheilkunde. 2025;242(02):105-115. doi:10.1055/a-2268-0985
BibTeX
@article{Lalos2025,
author = {Lalos, Fotios and Flühs, Dirk and Guberina, Maja and Bornfeld, Norbert and Stuschke, Martin and Sauerwein, Wolfgang and Bechrakis, Nikolaos E},
title = {Tumor- and Radiation-Related Complications after Ruthenium-106 Brachytherapy in Small to Medium Uveal Melanomas (Part 1)},
journal = {Klinische Monatsblätter für Augenheilkunde},
year = {2025},
volume = {242},
number = {02},
pages = {105--115},
doi = {10.1055/a-2268-0985}
}
EUVIMED